Long-term survival has been reported after myeloablative allogeneic HSCT; however, the high treatment-related mortality (TRM) associated with such an approach might lead to a premature abandonment. 3 Tandem autologous HSCT followed by a reduced-intensity conditioning (RIC) allogeneic HSCT has emerged as an alternative approach to avoid the high upfront TRM with myeloablative transplantation. Results from prospective randomized trials comparing tandem autologous/RIC allogeneic HSCT to tandem double autologous HSCT have been conflicting and relapse after transplant continues to be a major hurdle. 4, 5 The differences in conditioning regimens, GVHD prophylaxis and duration of follow-up between studies have hampered our ability to assess the impact of GVM effect when comparing the outcomes of allogeneic and autologous HSCT. To evaluate the impact of GVM effect, we retrospectively assessed the long-term outcomes of 74 consecutive patients under the age of 60 who underwent autologous (n ¼ 46) or related allogeneic HSCT (n ¼ 28) between March 1994 and December 2000. All the patients received single identical myeloablative conditioning regimen of TBI (3 Gy daily on day À10 to day À8), oral BU 2.4 mg/kg per day (day À7 to day À4) and CY 60 mg/kg i.v. daily (day À3 and day À2). GVHD prophylaxis consisted uniformly of a calcineurin inhibitor (tacrolimus or CYA) and MTX. No significant differences were observed between groups except for younger patients in the allogeneic group (Table 1) . With a median follow-up of 10 years, the allogeneic group had superior median progression-free survival (PFS) over the autologous Figure 1a ). There was no difference in overall survival (OS) between the autologous group and the allogeneic group (median OS of 5.7 and 5.8 years, respectively, P ¼ 0.42). The TRM at day 100 was 7% in autologous recipients and 22% in allogeneic recipients. The cumulative incidence of relapse was 17 and 76%, respectively (P ¼ 0.001) (Figure 1b) whereas the cumulative incidence of non-relapse mortality (NRM) was 32 and 11% (P ¼ 0.001) in the allogeneic and autologous groups, respectively. The cumulative incidence of acute GVHD (grades II-IV) was 46% and the cumulative incidence of chronic GVHD was 73%. Recently, Bahlis et al. 6 reported the outcomes in 15 (13 allogeneic and 2 matched unrelated) patients with multiple myeloma (60% with progressive disease at the time of transplant) who underwent HSCT with myeloablative preparative regimen of fludarabine, BU and thymoglobulin. The TRM with this regimen was 6.6%. After a median follow-up of 40.9 months, the estimated OS and PFS at 4 years was 38.9 and 20.0%, respectively. Recent advances in supportive care and novel myeloablative preparative regimens with reduced toxicity may reduce NRM while harnessing GVM effect. 6, 7 To assess the impact of high TRM in our cohort on the long-term outcomes, we reanalyzed the survival after excluding patients that died within the first 100 days (six in allogeneic group and three in the autologous group). We found a median PFS of 1.8 years in the autologous group and 8.2 years in the allogeneic group (P ¼ 0.003). Similarly, we found a trend toward improved OS in the allogeneic group; 5.8 versus 10 years (P ¼ 0.21). The superior long-term PFS and lower relapse rate in the allogeneic group strongly suggest a GVM effect. However, the early TRM in the allogeneic group offsets the OS benefit. This was more evident after the exclusion of patients that died within first 100 days. It may be appropriate to revisit myeloablative allogeneic transplantation as a treatment option for multiple myeloma in particular in the era of novel agents where the initial overall response to induction therapy exceeds 80%. 8 High-risk patients with unfavorable cytogenetics, high-risk gene expression profiling or relapsed disease may be appropriate candidates for such approach in prospective clinical trials. Letter to the Editor
